| Standard not met | Reason | Action being taken by the Pharmacy | By when | Notification By Pharmacy Improvements Made |
|---|---|---|---|---|
| 1.2 | The pharmacy does not carry out regular audits of the services it provides. This includes for the clinical decisions made relating to the supply of pharmacy-only medicines (P-medicines). So, the pharmacy is unable show how it continually monitors and improves the safety and quality its services. |
New SOPs to be produced for high-risk pharmacy medicines including Codeine-containing products, Stimulant laxatives, Cinnarazine/Phenergan and similar medicines. SOPS will state acceptable forms of ID, purchase frequency limits and include risk assessments. The new SOPs will form the basis against which a clinical audit will be carried out. Procedures are currently in place but will be formalised in the SOPs. Regarding clinical Audit, audits of the rejection or approval process of 20 pharmacy medicines sales (10 of each) to determine if the SOPs were followed correctly. |
15/05/2025 | 14/05/2025 |
| 4.2 | The pharmacy does not carry out identity checks on all of the P-medicines it supplies. This means that it cannot ensure that all supplies of P-medicines are to appropriately aged recipients and that the person supplied with the medication is who they claim to be. |
Photo ID for age-verification to be requested for all high-risk medicines such as Migraleve, Cinnarizine, Phenergan and Stimulant Laxatives such as Senokot Max and any future products advertised that fall under the same category. For lower risk medicines, checks will be completed using alternative methods such as card payment types and highlighting further the information relating to age restrictions on use and purchase. |
15/05/2025 | 14/05/2025 |
Pharmacy inspections
Inspection reports and learning from inspections